346 related articles for article (PubMed ID: 23863691)
1. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
[TBL] [Abstract][Full Text] [Related]
2. [Targeted therapies and radiation therapy in non-small cell lung cancer].
Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
[TBL] [Abstract][Full Text] [Related]
3. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
Baselga J
Ann Oncol; 2008 Sep; 19 Suppl 7():vii281-8. PubMed ID: 18790967
[No Abstract] [Full Text] [Related]
4. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.
Walker AJ; Alcorn SR; Narang AK; Nugent KM; Wild AT; Herman JM; Tran PT
Curr Probl Cancer; 2013; 37(5):301-12. PubMed ID: 24331186
[TBL] [Abstract][Full Text] [Related]
6. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
7. Combination Strategies to Improve Targeted Radionuclide Therapy.
Chan TG; O'Neill E; Habjan C; Cornelissen B
J Nucl Med; 2020 Nov; 61(11):1544-1552. PubMed ID: 33037092
[TBL] [Abstract][Full Text] [Related]
8. Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?
Riesterer O; Tenzer A; Zingg D; Hofstetter B; Vuong V; Pruschy M; Bodis S
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):361-8. PubMed ID: 14751504
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
Kabakov AE; Kudriavtsev VA; Makarova IuM
Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
[TBL] [Abstract][Full Text] [Related]
10. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.
George TJ; Franke AJ; Chakravarthy AB; Das P; Dasari A; El-Rayes BF; Hong TS; Kinsella TJ; Landry JC; Lee JJ; Monjazeb AM; Jacobs SA; Raben D; Rahma OE; Williams TM; Wu C; Coleman CN; Vikram B; Ahmed MM
Cancer; 2019 Aug; 125(16):2732-2746. PubMed ID: 31017664
[TBL] [Abstract][Full Text] [Related]
11. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
Hatake K; Tokudome N; Ito Y
Breast Cancer; 2007; 14(2):132-49. PubMed ID: 17485898
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted radiosensitisers in cancer treatment.
Zaidi SH; Huddart RA; Harrington KJ
Curr Drug Discov Technol; 2009 Jun; 6(2):103-34. PubMed ID: 19519337
[TBL] [Abstract][Full Text] [Related]
13. Novel chemoradiosensitizers for cancer therapy.
Page P; Yang LX
Anticancer Res; 2010 Sep; 30(9):3675-82. PubMed ID: 20944153
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization of prostate cancer by soy isoflavones.
Raffoul JJ; Sarkar FH; Hillman GG
Curr Cancer Drug Targets; 2007 Dec; 7(8):759-65. PubMed ID: 18220535
[TBL] [Abstract][Full Text] [Related]
15. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.
Chang L; Graham PH; Hao J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
Cancer Metastasis Rev; 2014 Sep; 33(2-3):469-96. PubMed ID: 24445654
[TBL] [Abstract][Full Text] [Related]
16. Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.
Searle EJ; Illidge TM; Stratford IJ
Clin Oncol (R Coll Radiol); 2014 May; 26(5):266-76. PubMed ID: 24602563
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.
Alberti C
G Chir; 2015; 36(3):133-6. PubMed ID: 26188759
[TBL] [Abstract][Full Text] [Related]
18. Targeted radiosensitization in prostate cancer.
Ghotra VP; Geldof AA; Danen EH
Curr Pharm Des; 2013; 19(15):2819-28. PubMed ID: 23448469
[TBL] [Abstract][Full Text] [Related]
19. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
[TBL] [Abstract][Full Text] [Related]
20. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
